Edwards Lifesciences Corporation (EW)

NYSE: EW · Real-Time Price · USD

90.21

+0.26 (0.29%)

At close: Aug 28, 2026, 4:00 PM EDT

91.14

+0.93 (1.03%)

After-hours: Aug 28, 2026, 7:50 PM EDT

Edwards Lifesciences Financials Overview

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	6,512	6,068	5,440	5,010	4,464	5,233
Revenue Growth	14.55%	11.55%	8.57%	12.23%	-14.69%	19.29%
Gross Profit	5,069	4,733	4,322	4,032	3,742	3,984
Operating Income	1,831	1,638	1,481	1,487	1,542	1,587
Net Income	1,005	1,074	4,175	1,402	1,522	1,503
Earnings Per Share	1.72	1.83	6.97	2.30	2.44	2.38
EPS Growth	-75.50%	-73.70%	202.39%	-5.44%	2.40%	83.08%

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Transcatheter Aortic Valve Replacement	4,766	4,488	4,106	3,880	3,518	3,423
Transcatheter Mitral and Tricuspid Therapies	674.6	550.6	352.1	197.6	116.1	86
Surgical Structural Heart	1,072	1,029	981.3	932.6	829.7	889.1
Revenue (Total)	6,512	6,068	5,440	5,010	4,464	5,233

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Investments	4,282	4,233	3,981	1,633	1,215	1,467
Total Debt	704.4	705.4	700	685.1	691.3	690.3
Net Cash (Debt)	3,577	3,528	3,281	947.7	524	776.5
Net Cash Growth	6.31%	7.51%	246.25%	80.86%	-32.52%	9.72%
Net Cash Per Share	6.15	6.02	5.48	1.56	0.84	1.23

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Cash Flow	1,720	1,595	542.3	895.8	1,218	1,732
Capital Expenditures	-286.7	-260.2	-252.4	-253	-244.6	-325.8
Free Cash Flow	1,434	1,335	289.9	642.8	973.6	1,406
Free Cash Flow Growth	143.85%	360.50%	-54.90%	-33.98%	-30.77%	117.26%

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Gross Margin	77.84%	78.01%	79.46%	80.47%	83.82%	76.13%
Operating Margin	28.12%	26.99%	27.22%	29.69%	34.54%	30.32%
Pretax Margin	21.77%	20.98%	28.46%	27.39%	34.04%	32.53%
Profit Margin	15.43%	17.69%	76.75%	27.99%	34.09%	28.73%
FCF Margin	22.01%	22.00%	5.33%	12.83%	21.81%	26.88%

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Aug '26 Aug 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
PE Ratio	53.82	46.08	10.46	32.98	30.31	53.81
Forward PE	28.73	30.93	31.19	28.41	30.35	52.98
P/FCF Ratio	36.27	37.06	150.61	71.94	47.38	57.51
PS Ratio	7.98	8.15	8.03	9.23	10.33	15.46